Nuclear accumulation of Yes-Associated Protein (YAP) maintains the survival of doxorubicin-induced senescent cells by promoting survivin expression

Cancer Letters

Volumn 375, Issue 1, 2016, Pages 84-91

  Ma, Kai ^a   Xu, Qing ^a   Wang, Shuren ^a   Zhang, Weina ^a   Liu, Mei ^a   Liang, Shufang ^b   Zhu, Hongxia ^a   Xu, Ningzhi ^a,b  

^a CANCER HOSPITAL   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Doxorubicin; Senescence; Survivin; YAP

Indexed keywords

DOXORUBICIN; SURVIVIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; ANTINEOPLASTIC ANTIBIOTIC; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL NUCLEUS; CELL SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; EXTRACELLULAR MATRIX; HCT116 CELL LINE; HELA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; ACTIVE TRANSPORT; CELL AGING; DRUG RESISTANCE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; TRANSCRIPTION INITIATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIBIOTICS, ANTINEOPLASTIC; CELL AGING; CELL NUCLEUS; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HELA CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; PHOSPHOPROTEINS; TRANSCRIPTIONAL ACTIVATION;

EID: 84960357921     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.02.045     Document Type: Article

References (58)

1. Ben-Porath I., Weinberg R.A. When cells get stressed: an integrative view of cellular senescence. J. Clin. Invest 2004, 113:8-13.
2. Itahana K., Dimri G., Campisi J. Regulation of cellular senescence by p53. Eur. J. Biochem 2001, 268:2784-2791.
3. Zhou Q., Hong Y., Zhan Q., Shen Y., Liu Z. Role for Kruppel-like factor 4 in determining the outcome of p53 response to DNA damage. Cancer Res 2009, 69:8284-8292.
4. Chang B.D., Broude E.V., Dokmanovic M., Zhu H., Ruth A., Xuan Y., et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 1999, 59:3761-3767.
5. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains. Exp. Cell Res 1961, 25:585-621.
6. Smith J.R., Pereira-Smith O.M. Replicative senescence: implications for in vivo aging and tumor suppression. Science 1996, 273:63-67.
7. Robles S.J., Adami G.R. Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene 1998, 16:1113-1123.
8. Chang B.D., Swift M.E., Shen M., Fang J., Broude E.V., Roninson I.B. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:389-394.
9. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
10. Michaloglou C., Vredeveld L.C., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M., et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
11. Braig M., Lee S., Loddenkemper C., Rudolph C., Peters A.H., Schlegelberger B., et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005, 436:660-665.
12. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., et al. Tumour biology: senescence in premalignant tumours. Nature 2005, 436:642.
13. Tacar O., Sriamornsak P., Dass C.R. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J. Pharm. Pharmacol 2013, 65:157-170.
14. Coppe J.P., Patil C.K., Rodier F., Sun Y., Munoz D.P., Goldstein J., et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008, 6:2853-2868.
15. Coppe J.P., Desprez P.Y., Krtolica A., Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol 2010, 5:99-118.
16. Canino C., Mori F., Cambria A., Diamantini A., Germoni S., Alessandrini G., et al. SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. Oncogene 2012, 31:3148-3163.
17. Bavik C., Coleman I., Dean J.P., Knudsen B., Plymate S., Nelson P.S. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res 2006, 66:794-802.
18. Liu D., Hornsby P.J. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res 2007, 67:3117-3126.
19. Campisi J., d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol 2007, 8:729-740.
20. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660.
21. Dorr J.R., Yu Y., Milanovic M., Beuster G., Zasada C., Dabritz J.H.M., et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature 2013, 501:421-425.
22. Mo J.S., Meng Z., Kim Y.C., Park H.W., Hansen C.G., Kim S., et al. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nat. Cell Biol 2015, 17:500-510.
23. Pan D. The hippo signaling pathway in development and cancer. Dev. Cell 2010, 19:491-505.
24. Zhao B., Li L., Lei Q., Guan K.L. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 2010, 24:862-874.
25. Dong J., Feldmann G., Huang J., Wu S., Zhang N., Comerford S.A., et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007, 130:1120-1133.
26. Hao Y., Chun A., Cheung K., Rashidi B., Yang X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J. Biol. Chem 2008, 283:5496-5509.
27. Zhao B., Ye X., Yu J., Li L., Li W., Li S., et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008, 22:1962-1971.
28. Moroishi T., Hansen C.G., Guan K.L. The emerging roles of YAP and TAZ in cancer. Nat. Rev. Cancer 2015, 15:73-79.
29. Aragona M., Panciera T., Manfrin A., Giulitti S., Michielin F., Elvassore N., et al. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell 2013, 154:1047-1059.
30. Rebbaa A., Zheng X., Chou P.M., Mirkin B.L. Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene 2003, 22:2805-2811.
31. Basu D., Reyes-Mugica M., Rebbaa A. Role of the beta catenin destruction complex in mediating chemotherapy-induced senescence-associated secretory phenotype. PLoS ONE 2012, 7:e52188.
32. Stegmaier K., Wong J.S., Ross K.N., Chow K.T., Peck D., Wright R.D., et al. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med 2007, 4:e122.
33. Xie Q., Chen J., Feng H., Peng S., Adams U., Bai Y., et al. YAP/TEAD-mediated transcription controls cellular senescence. Cancer Res 2013, 73:3615-3624.
34. Zhang H., Liu C.Y., Zha Z.Y., Zhao B., Yao J., Zhao S., et al. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J. Biol. Chem 2009, 284:13355-13362.
35. Harvey K.F., Zhang X., Thomas D.M. The Hippo pathway and human cancer. Nat. Rev. Cancer 2013, 13:246-257.
36. Johnson R., Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat. Rev. Drug Discov 2014, 13:63-79.
37. Azzolin L., Panciera T., Soligo S., Enzo E., Bicciato S., Dupont S., et al. YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell 2014, 158:157-170.
38. Liu-Chittenden Y., Huang B., Shim J.S., Chen Q., Lee S.J., Anders R.A., et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev 2012, 26:1300-1305.
39. Krtolica A., Parrinello S., Lockett S., Desprez P.Y., Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:12072-12077.
40. Parrinello S., Coppe J.P., Krtolica A., Campisi J. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J. Cell Sci 2005, 118:485-496.
41. Vigneron A.M., Vousden K.H. An indirect role for ASPP1 in limiting p53-dependent p21 expression and cellular senescence. EMBO J. 2012, 31:471-480.
42. Fausti F., Di Agostino S., Cioce M., Bielli P., Sette C., Pandolfi P.P., et al. ATM kinase enables the functional axis of YAP, PML and p53 to ameliorate loss of Werner protein-mediated oncogenic senescence. Cell Death Differ 2013, 20:1498-1509.
43. Ciamporcero E., Shen H., Ramakrishnan S., Yu S., Ku S., Chintala L., et al. YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene 2015, 10.1038/onc.2015.219.
44. Zhang X., George J., Deb S., Degoutin J.L., Takano E.A., Fox S.B., et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene 2011, 30:2810-2822.
45. Yu F.X., Zhao B., Guan K.L. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 2015, 163:811-828.
46. Lai D., Ho K.C., Hao Y., Yang X. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res 2011, 71:2728-2738.
47. Touil Y., Igoudjil W., Corvaisier M., Dessein A.F., Vandomme J., Monte D., et al. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin. Cancer Res 2014, 20:837-846.
48. Lin L., Sabnis A.J., Chan E., Olivas V., Cade L., Pazarentzos E., et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat. Genet 2015, 47:250-256.
49. Ghosh S.K., Yigit M.V., Uchida M., Ross A.W., Barteneva N., Moore A., et al. Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma. Int. J. Cancer 2014, 134:1758-1766.
50. Vequaud E., Desplanques G., Jezequel P., Juin P., Barille-Nion S. Survivin contributes to DNA repair by homologous recombination in breast cancer cells. Breast Cancer Res. Treat 2016, 155:53-63.
51. Hu S., Fu S., Xu X., Chen L., Xu J., Li B., et al. The mechanism of radiosensitization by YM155, a novel small molecule inhibitor of survivin expression, is associated with DNA damage repair. Cell. Physiol. Biochem 2015, 37:1219-1230.
52. Cheung C.H., Huang C.C., Tsai F.Y., Lee J.Y., Cheng S.M., Chang Y.C., et al. Survivin - biology and potential as a therapeutic target in oncology. Onco Targets Ther 2013, 6:1453-1462.
53. Hewitt G., Jurk D., Marques F.D., Correia-Melo C., Hardy T., Gackowska A., et al. Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence. Nat. Commun 2012, 3:708.
54. Hershman D.L., Shao T. Anthracycline cardiotoxicity after breast cancer treatment. Oncology (Williston Park) 2009, 23:227-234.
55. Barrett-Lee P.J., Dixon J.M., Farrell C., Jones A., Leonard R., Murray N., et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann. Oncol 2009, 20:816-827.
56. Ye S., Eisinger-Mathason T.S. Targeting the Hippo pathway: clinical implications and therapeutics. Pharmacol. Res 2016, 103:270-278.
57. Clemens M.R., Gladkov O.A., Gartner E., Vladimirov V., Crown J., Steinberg J., et al. Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer. Breast Cancer Res. Treat 2015, 149:171-179.
58. Kelly R.J., Thomas A., Rajan A., Chun G., Lopez-Chavez A., Szabo E., et al. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol 2013, 24:2601-2606.